NCT02411643

Molecular Effects of Topical Calcipotriene on Morphea

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Northwestern University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will look into how topical treatment with synthetic Vitamin D3, calcipotriene ointment, used as standard of care, works in patients with morphea. Skin biopsies of morphea lesions before and after treatment with topical calcipotriene 0.005% ointment will be analyzed for changes in RNA and protein. A skin biopsy of unaffected skin will also be obtained and used for a control. This is an initial study to look at the molecular effects of topical calcipotriene on human morphea-involved skin. This study will look at the differences between affected and unaffected skin. This study also will look at clinical outcomes in morphea patients and determine if there are any clinical predictors for improvement with the medication.

Conditions

• Morphea
• Localized Scleroderma

Interventions

Type	Name	Description
DRUG	topical calcipotriene 0.005% ointment	Affected area will be treated twice daily for 3 months

Timeline

• Start date: 2015-03-01
• Primary completion: 2016-04-01
• Completion: 2016-04-01
• First posted: 2015-04-08
• Last updated: 2018-09-13
• Results posted: 2018-09-13

Locations

1 site across 1 country: United States